ArticleBMC endocrine disorders2026
Hsa-miR-5585-3p regulates the NLRP3 activation and the expression of cytokines through CHUK in a cellular model of diabetic kidney disease.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 20-40% of patients with diabetes mellitus (DM) develop diabetic kidney disease (DKD), a major microvascular complication of the condition. This study aimed to explore the potential diagnostic value of hsa-miR-5585-3p for DKD, and its regulatory effects, by targeting CHUK, on inflammatory factor expression and NLRP3 activation in HK-2 cells induced by high glucose (HG).
methodsThe expression profile of hsa-miR-5585-3p in the serum samples from patients with type 2 DM (T2DM) and DKD was analyzed by RT-qPCR. Correlation analysis between hsa-miR-5585-3p and UACR, eGFR, as well as inflammatory factors was investigated. Bioinformatics analysis predicted the downstream target genes of hsa-miR-5585-3p. The interaction between hsa-miR-5585-3p and CHUK was verified by dual luciferase reporter assay. An in vitro DKD model was established by exposing HK-2 cells to HG. The expression levels of inflammatory factors and the NLRP3 activation were detected by RT-qPCR, Western blot, or ELISA following modulation of the hsa-miR-5585-3p/CHUK axis.
resultsHsa-miR-5585-3p was significantly downregulated in the serum of DKD patients and showed correlations with UACR, eGFR, and inflammatory factors. In HK-2 cells stimulated by HG, hsa-miR-5585-3p suppressed the expression of inflammatory factors as well as key molecules in the NLRP3 pathway. Data from the rescue experiment supported the partial role of CHUK overexpression in counteracting the inhibition mediated by hsa-miR-5585-3p.
conclusionsHsa-miR-5585-3p may serve as a potential diagnostic biomarker for DKD, pending further validation. Moreover, hsa-miR-5585-3p regulated the inflammatory response and activation of the NLRP3 in HK-2 cells induced by HG through CHUK. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.